Information:
Fel:
ID
12357
Beskrivning
Study description: Study documentation part- Study termination. This is a phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS). Principal Investigator PD Dr. Tobias Grge, University Hospital of Mnster. EudraCT - Nr. 2012-000108-13.
Nyckelord
Versioner (1)
- 2015-11-11 2015-11-11 -
Uppladdad den
11 november 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination DRKS00004652
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination
- StudyEvent: ODM
Similar models
Riliva_CRF_EudraCT - Nr. 2012-000108-13-Study termination
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
date
Item
Date of termination:
date
Center number
Item
Center number:
integer
Item
Reasons for study termination
text
C0008972 (UMLS CUI [1,1])
C0013135 (UMLS CUI [1,2])
C1272707 (UMLS CUI [1,3])
C0013135 (UMLS CUI [1,2])
C1272707 (UMLS CUI [1,3])
CL Item
Revocation of Consent by patient (1)
CL Item
Early ending of the entire study (2)
CL Item
Lack of patient compliance (3)
CL Item
Fall in hemoglobin of more than 2 units [g / dL] from initial value and source of bleeding can not be stopped (4)
CL Item
Decision of the investigator that further participation of the patient in the study is not justifiable (5)
CL Item
Violation of inclusion or exclusion criteria after 1st dose study medication (6)
inclusion criteria; exclusion criteria
Item
Please mention the criteria, if inclusion or exclusion criteria is the reason for study drop out.
text
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,2])